ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

Urocidin May Provide Alternative To Cystectomy in BCG Cancers

May 27, 2011

Overall Cancer Mortality Rates Higher For Men Than Women

July 29, 2011

MSKCC hopes to raise $1 billion in five-year campaign.

November 7, 2003

November issue of Business & Regulatory Report, an additional 8 pages, included in this issue.

November 19, 2004

The Meeting Worth Lobbying For: A “PRG” For Disease-Specific Review; NCI Plans Six.

June 23, 2000

NCAB Needs Focus, Strong Membership To Better Advise NCI, Chairman Rimer Says

September 22, 1995